Improving the Cytotoxic Activity of Hinokitiol from Drug-Loaded Phytosomal Formulation Against Breast Cancer Cell Lines

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2024 Oct 17

PMID 39415963

Authors

Tarek A Ahmed

Ghada A Milibary

Alshaimaa M Almehmady

Amerh A Alahmadi

Ehab M M Ali

Khalid M El-Say

Affiliations

Soon will be listed here.

Abstract

Background: This study investigates the influence of various formulation parameters on the characteristics of hinokitiol-loaded phytosomes and evaluates their anticancer potential against breast cancer cells.

Materials And Methods: Phytosomal nanoparticles were prepared and characterized for size, zeta potential, and entrapment efficiency. Morphological analysis was conducted using optical microscopy and transmission electron microscopy (TEM). The solubility of hinokitiol at different pH levels was determined, and the in vitro release profile of the optimized phytosomes was assessed. Cytotoxicity assays were performed to evaluate the anticancer efficacy against breast cancer cell lines, and apoptosis induction was examined using Annexin V/propidium iodide staining. Cell cycle analysis was conducted to assess the impact on cell cycle progression.

Results: The optimized phytosomes demonstrated a size range of 138.4 ± 7.7 to 763.7 ± 15.4 nm, with zeta potentials ranging from -10.2 ± 0.28 to -53.2 ± 1.06 mV and entrapment efficiencies between 29.161 ± 1.163% and 92.77 ± 7.01%. Morphological characterization confirmed uniformity and spherical morphology. Hinokitiol solubility increased with pH, and the release from the optimized phytosomes exhibited sustained patterns. The formulated phytosomes showed superior cytotoxicity, with lower IC50 values compared to pure hinokitiol. Treatment induced significant apoptosis and cell cycle arrest at the G2/M and S phases.

Conclusion: Hinokitiol-loaded phytosomes demonstrate promising anticancer efficacy against breast cancer cells, highlighting their potential as targeted therapeutic agents for breast cancer therapy.

References

Wlodkowic D, Telford W, Skommer J, Darzynkiewicz Z . Apoptosis and beyond: cytometry in studies of programmed cell death. Methods Cell Biol. 2011; 103:55-98. PMC: 3263828. DOI: 10.1016/B978-0-12-385493-3.00004-8. View

Maes A, Menu E, de Veirman K, Maes K, Vand Erkerken K, de Bruyne E . The therapeutic potential of cell cycle targeting in multiple myeloma. Oncotarget. 2017; 8(52):90501-90520. PMC: 5685770. DOI: 10.18632/oncotarget.18765. View

Kari S, Subramanian K, Altomonte I, Murugesan A, Yli-Harja O, Kandhavelu M . Programmed cell death detection methods: a systematic review and a categorical comparison. Apoptosis. 2022; 27(7-8):482-508. PMC: 9308588. DOI: 10.1007/s10495-022-01735-y. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Fried J, Perez A, Clarkson B . Flow cytofluorometric analysis of cell cycle distributions using propidium iodide. Properties of the method and mathematical analysis of the data. J Cell Biol. 1976; 71(1):172-81. PMC: 2109736. DOI: 10.1083/jcb.71.1.172. View

Ahmed T . Preparation of transfersomes encapsulating sildenafil aimed for transdermal drug delivery: Plackett-Burman design and characterization. J Liposome Res. 2014; 25(1):1-10. DOI: 10.3109/08982104.2014.950276. View

Ali A, Manzoor M, Ahmad N, Aadil R, Qin H, Siddique R . The Burden of Cancer, Government Strategic Policies, and Challenges in Pakistan: A Comprehensive Review. Front Nutr. 2022; 9:940514. PMC: 9355152. DOI: 10.3389/fnut.2022.940514. View

Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M . Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022; 66:15-23. PMC: 9465273. DOI: 10.1016/j.breast.2022.08.010. View

He H, Lu Y, Qi J, Zhu Q, Chen Z, Wu W . Adapting liposomes for oral drug delivery. Acta Pharm Sin B. 2019; 9(1):36-48. PMC: 6362257. DOI: 10.1016/j.apsb.2018.06.005. View

10.

Ligasova A, Frydrych I, Koberna K . Basic Methods of Cell Cycle Analysis. Int J Mol Sci. 2023; 24(4). PMC: 9963451. DOI: 10.3390/ijms24043674. View

11.

Sabit H, Abdel-Hakeem M, Shoala T, Abdel-Ghany S, Abdel-Latif M, Almulhim J . Nanocarriers: A Reliable Tool for the Delivery of Anticancer Drugs. Pharmaceutics. 2022; 14(8). PMC: 9415391. DOI: 10.3390/pharmaceutics14081566. View

12.

Jan R, Chaudhry G . Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics. Adv Pharm Bull. 2019; 9(2):205-218. PMC: 6664112. DOI: 10.15171/apb.2019.024. View

13.

El-Say K, Alamri S, Alsulimani H, Alharbi W, Omar A, Safo M . Incorporating valsartan in sesame oil enriched self-nanoemulsifying system-loaded liquisolid tablets to improve its bioavailability. Int J Pharm. 2023; 639:122966. DOI: 10.1016/j.ijpharm.2023.122966. View

14.

Elmore S . Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007; 35(4):495-516. PMC: 2117903. DOI: 10.1080/01926230701320337. View

15.

Sorrenti V, Buro I, Consoli V, Vanella L . Recent Advances in Health Benefits of Bioactive Compounds from Food Wastes and By-Products: Biochemical Aspects. Int J Mol Sci. 2023; 24(3). PMC: 9916361. DOI: 10.3390/ijms24032019. View

16.

Li L, Wu P, Lee J, Li P, Hsieh W, Ho C . Hinokitiol induces DNA damage and autophagy followed by cell cycle arrest and senescence in gefitinib-resistant lung adenocarcinoma cells. PLoS One. 2014; 9(8):e104203. PMC: 4126702. DOI: 10.1371/journal.pone.0104203. View

17.

Ali E, Elashkar A, El-Kassas H, Salim E . Methotrexate loaded on magnetite iron nanoparticles coated with chitosan: Biosynthesis, characterization, and impact on human breast cancer MCF-7 cell line. Int J Biol Macromol. 2018; 120(Pt A):1170-1180. DOI: 10.1016/j.ijbiomac.2018.08.118. View

18.

Rieger A, Nelson K, Konowalchuk J, Barreda D . Modified annexin V/propidium iodide apoptosis assay for accurate assessment of cell death. J Vis Exp. 2011; (50). PMC: 3169266. DOI: 10.3791/2597. View

19.

Ghose S, Radhakrishnan V, Bhattacharya S . Ethics of cancer care: beyond biology and medicine. Ecancermedicalscience. 2019; 13:911. PMC: 6467456. DOI: 10.3332/ecancer.2019.911. View

20.

Tefas L, Sylvester B, Tomuta I, Sesarman A, Licarete E, Banciu M . Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach. Drug Des Devel Ther. 2017; 11:1605-1621. PMC: 5448697. DOI: 10.2147/DDDT.S129008. View